Loading the records…
Loading the records…
The EPIC Act of 2025 would extend small-molecule drug exclusivity before Medicare price negotiation from 7 to 11 years for drugs approved after 2028. Despite sector-wide 30-day declines ($MRK -7.18%, $GSK -5.02%, $PFE -4.24%), the bill's early-stage status (referred to Senate Finance Committee) and long legislative path mean no near-term revenue impact. The structural beneficiary is clear: small-molecule-focused pharma pipelines gain 4 additional years of un-negotiated pricing.
Despite the 30-day declines in $MRK (-7.18% to $111.66), $PFE (-4.24% to $26.89), and $GSK (-5.02% to $52.42), the EPIC Act is a material structural positive for small-molecule pharma. Investors should view the current pullback as a potential entry point if legislative momentum builds. However, the bill is early-stage, and any near-term bounce would be speculative. Watch for: Senate Finance Committee markup, companion House bill introduction, and CBO score. The 2028 implementation date means no revenue impact for at least 2 years post-enactment, limiting near-term catalysts.
WHAT HAPPENED: On March 4, 2025, Sen. Tillis (R-NC) introduced S.832, the EPIC Act of 2025, in the 119th Congress. The bill was read twice and referred to the Senate Committee on Finance. It has 7 cosponsors (all Republicans). The bill amends Section 1192(e)(1)(A)(ii) of the Social Security Act to extend the market approval period required before a small-molecule drug qualifies for Medicare price negotiation. For 2026-2027, the 7-year threshold remains. Starting in 2028, the threshold rises to 11 years—matching the current 11-year threshold for biologics.
THE MONEY TRAIL: This bill does not authorize or appropriate any direct federal spending. It is a regulatory change that defers mandatory price negotiation by four years per qualifying small-molecule drug. The financial impact is indirect: it preserves higher revenue for drug manufacturers on post-2028 approved small-molecule drugs by delaying CMS's ability to force discounts. No money leaves the Treasury due to this bill; rather, CMS's negotiation authority is postponed. The Congressional Budget Office would score this as a decrease in direct spending (Medicare pays more for drugs) and likely an increase in premiums.
STRUCTURAL WINNERS AND LOSERS: Winners are pharmaceutical companies with robust small-molecule pipelines expected to gain FDA approval after 2028. $MRK (Merck), $PFE (Pfizer), and $GSK (GSK) are primary beneficiaries given their large small-molecule R&D portfolios. $LLY (Eli Lilly) is also relevant though ticker not in provided data—its small-molecule pipeline includes obesity/diabetes candidates. Losers include CMS and Medicare beneficiaries who would wait longer for negotiated prices on new small-molecule drugs. Biosimilar and generic manufacturers are also disadvantaged as branded small-molecule exclusivity extends.
REAL MARKET DATA: As of April 30, 2026, $MRK trades at $111.66 (down 7.18% over 30 days, with a sharp drop from $119.07 on April 17). $PFE at $26.89 (down 4.24% over 30 days, declining steadily from $27.56). $GSK at $52.42 (down 5.02% over 30 days, with a notable drop from $54.47 on April 28 to $51.40 April 29). These declines occurred despite the bill being introduced—reflecting that the bill is early-stage and not a near-term catalyst. The market is pricing in other headwinds (patent cliffs, pipeline risks) rather than this legislative tailwind.
TIMELINE: The bill is in early-stage. It must pass the Senate Finance Committee (Chairman Grassley, R-IA has not publicly committed), then the full Senate, then the House (where a companion bill has not been introduced), and be signed by the President. With 7 Republican cosponsors and a 2028 implementation date, the bill has moderate low-term potential but faces significant hurdles this Congress given partisan disagreement over IRA drug pricing provisions.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
ABC Safe Drug Act
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →